Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment

Blood

Volumn 101, Issue 2, 2003, Pages 466-468

  Rubenstein, James L ^a   Combs, Dan ^a   Rosenberg, Jay ^a   Levy, Arthur ^a   McDermott, Michael ^a   Damon, Lloyd ^a   Ignoffo, Robert ^a   Aldape, Kenneth ^a   Shen, Arthur ^a   Lee, Dana ^a   Grillo Lopez, Antonio ^a   Shuman, Marc A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; MENINGITIS; MONKEY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REPRODUCIBILITY;

EID: 0037438494     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1636     Document Type: Article

References (16)

1. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178-1184.
2. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993;119:1093-1104.
3. Chamberlain MC, Kormanik P, Glantz M. Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol Rep. 1998;5:521-525.
4. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
5. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
6. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
8. Reff M, Carner K, Chambers KS. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
9. Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol. 1979;6: 207-213.
10. Youle R. Immunotoxins for central nervous system malignancy. Semin Cancer Biol. 1996;7:65-70.
11. Wood JH, Poplack DG, Bleyer WA, Ommaya AK. Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science. 1977;195:499-501.
12. Poplack DG, Bleyer WA, Wood JH, et al. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res. 1977;37:1982-1985.
13. Kramer K, Cheung N-K, Humm J, et al. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J Neurooncol. 1997;35:101-111.
14. Rubenstein JL, Rosenberg J, Damon L. High-dose methotrexate plus rituximab (anti-CD20) monoclonal antibody in the treatment of primary CNS lymphoma [abstract]. Society for Neuro-Oncology Fourth Annual Meeting; November 17-21, 1999; Scottdale, AZ.
15. Trbojevic-Cepe M, Brinar V, Pauro M, et al. Cerebrospinal fluid complement activation in neurological diseases. J Neurol Sci. 1998;154:173-181.
16. Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965;7:308-313.